Author + information
- Received April 7, 2010
- Revision received June 29, 2010
- Accepted July 5, 2010
- Published online February 1, 2011.
- Franz H. Messerli, MD⁎,⁎ (, )
- Harikrishna Makani, MD⁎,
- Alexandre Benjo, MD⁎,
- Jorge Romero, MD⁎,
- Carlos Alviar, MD⁎ and
- Sripal Bangalore, MD, MHA†
- ↵⁎Reprint requests and correspondence:
Dr. Franz H. Messerli, Hypertension Program, Division of Cardiology, St. Luke's-Roosevelt Hospital, Columbia University College of Physicians and Surgeons, 1000 10th Avenue, Suite 3B-30, New York, New York 10019
Objectives The purpose of this study was to evaluate the antihypertensive efficacy of hydrochlorothiazide (HCTZ) by ambulatory blood pressure (BP) monitoring.
Background HCTZ is the most commonly prescribed antihypertensive drug worldwide. More than 97% of all HCTZ prescriptions are for 12.5 to 25 mg per day. The antihypertensive efficacy of HCTZ by ambulatory BP monitoring is less well defined.
Methods A systematic review was made using Medline, Cochrane, and Embase for all the randomized trials that assessed 24-h BP with HCTZ in comparison with other antihypertensive drugs.
Results Fourteen studies of HCTZ dose 12.5 to 25 mg with 1,234 patients and 5 studies of HCTZ dose 50 mg with 229 patients fulfilled the inclusion criteria. The decrease in 24-h BP with HCTZ dose 12.5 to 25 mg was systolic 6.5 mm Hg (95% confidence interval: 5.3 to 7.7 mm Hg) and diastolic 4.5 mm Hg (95% confidence interval: 3.1 to 6.0 mm Hg) and was inferior compared with the 24-h BP reduction of angiotensin-converting enzyme inhibitors (mean BP reduction 12.9/7.7 mm Hg; p < 0.003), angiotensin-receptor blockers (mean BP reduction 13.3/7.8 mm Hg; p < 0.001), beta-blockers (mean BP reduction 11.2/8.5 mm Hg; p < 0.00001), and calcium antagonists (mean BP reduction 11.0/8.1 mm Hg; p < 0.05). There was no significant difference in both systolic (p = 0.30) and diastolic (p = 0.15) 24-h BP reduction between HCTZ 12.5 mg (5.7/3.3 mm Hg) and HCTZ 25 mg (7.6/5.4 mm Hg). However, with HCTZ 50 mg, the reduction in 24-h BP was significantly higher (12.0/5.4 mm Hg) and was comparable to that of other agents.
Conclusions The antihypertensive efficacy of HCTZ in its daily dose of 12.5 to 25 mg as measured in head-to-head studies by ambulatory BP measurement is consistently inferior to that of all other drug classes. Because outcome data at this dose are lacking, HCTZ is an inappropriate first-line drug for the treatment of hypertension.
Dr. Messerli reports that he has served as an ad hoc consultant for Novartis, Boehringer Ingelheim, Daiichi Sankyo, Sanofi, and Takeda; and has received research funding and grants from Novartis, Boehringer Ingelheim, and Forest. All other authors have reported that they have no relationships to disclose. None of the authors received any compensation for their work on this manuscript.
- Received April 7, 2010.
- Revision received June 29, 2010.
- Accepted July 5, 2010.
- American College of Cardiology Foundation